{"id":10328,"date":"2026-09-29T06:34:22","date_gmt":"2026-09-29T11:34:22","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10328"},"modified":"2026-09-29T06:40:53","modified_gmt":"2026-09-29T11:40:53","slug":"nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/","title":{"rendered":"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10328\" class=\"elementor elementor-10328\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul type=\"disc\"><li><i>Samarendra Mohanty, Co-Founder, President and Chief Scientific Officer, to participate in the premier cell and gene therapy industry conference, October 5\u20137, 2026, in Phoenix, Arizona<\/i><\/li><\/ul><p><span class=\"legendSpanClass\">DALLAS<\/span>,\u00a0<span class=\"legendSpanClass\">Sept. 29, 2026<\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Terap\u00e9utica del nanoscopio<\/a>, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Samarendra Mohanty, Co-Founder, President and Chief Scientific Officer, will deliver an Innovation Spotlight presentation at the\u00a0<a href=\"https:\/\/meetingonthemesa.com\/\" target=\"_blank\" rel=\"nofollow noopener\">Cell &amp; Gene Meeting on the Mesa 2026<\/a>, taking place October 5\u20137, 2026\u00a0<b>in Phoenix, Arizona<\/b>. The meeting is organized by the\u00a0<a href=\"https:\/\/alliancerm.org\/\" target=\"_blank\" rel=\"nofollow noopener\">Alliance for Regenerative Medicine<\/a>\u00a0(ARM), which unites the cell and gene therapy ecosystem to modernize healthcare systems, overcome obstacles to innovation, and improve patient access to life-changing treatments.<\/p><p><b>Detalles de la presentaci\u00f3n:<\/b><\/p><p><b>Cell &amp; Gene Meeting on the Mesa 2026<br class=\"dnr\" \/><\/b><b>Sesi\u00f3n:\u00a0<\/b>Innovation Spotlights<br class=\"dnr\" \/><b>Presentador:\u00a0<\/b>Samarendra Mohanty, President<br class=\"dnr\" \/><b>Fecha y hora:\u00a0<\/b>Tuesday, October 6, 2026, 11:15 AM<br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>The Arizona Biltmore Hotel, Phoenix, Arizona<\/p><p>During his presentation, Dr. Mohanty will provide a company update on Nanoscope&#8217;s progress toward potential global approval of its lead asset, MOGENRY<sup>\u00ae\u00a0<\/sup>(sonpiretigene isteparvovec; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">Company&#8217;s Biologics License Application (BLA), currently under FDA review.<\/a>\u00a0Members of the Nanoscope leadership will be available to meet.\u00a0Investors and potential partners should schedule a meeting via the partnering App or reach out to Nanoscope directly.<\/p><p><b>About MOGENRY (sonpiretigene isteparvovec; MCO-010)<br \/><\/b>La tecnolog\u00eda de opsina multicaracter\u00edstica (MCO) de Nanoscope utiliza una opsina sint\u00e9tica patentada, modificada gen\u00e9ticamente, para optimizar su rendimiento en t\u00e9rminos de alta sensibilidad a la luz en un amplio espectro y una cin\u00e9tica r\u00e1pida. Tras la concepci\u00f3n e invenci\u00f3n de la tecnolog\u00eda por parte de Samarendra Mohanty, cofundador, presidente y director cient\u00edfico de Nanoscope, su equipo ha dedicado m\u00e1s de una d\u00e9cada a evaluar su rendimiento en diversos modelos animales y enfermedades humanas. MOGENRY es una terapia g\u00e9nica optogen\u00e9tica intrav\u00edtrea experimental, de una sola aplicaci\u00f3n y administrada en consulta, basada en la plataforma MCO de Nanoscope. Al administrar un gen de opsina multicaracter\u00edstica a las c\u00e9lulas bipolares de la retina, de alta densidad, MOGENRY confiere a estas c\u00e9lulas supervivientes sensibilidad directa a la luz, permiti\u00e9ndoles utilizar el circuito visual restante tras la p\u00e9rdida de fotorreceptores. MOGENRY no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, y est\u00e1 dise\u00f1ado para su administraci\u00f3n dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><b>Acerca de Nanoscope Therapeutics<br \/><\/b>Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b\/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">FDA has accepted and filed the Company&#8217;s BLA for MOGENRY<\/a>. If approved, MOGENRY has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA).<\/p><p><b>Contacto:<br \/><\/b>Nanoscope Therapeutics, Inc<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><u><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/u><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Samarendra Mohanty, Co-Founder, President and Chief Scientific Officer, to participate in the premier cell and gene therapy industry conference, October 5\u20137, 2026, in Phoenix, Arizona DALLAS,\u00a0Sept. 29, 2026\u00a0 &#8212; Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10329,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at Meeting on the Mesa 2026 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T11:34:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T11:40:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026\",\"datePublished\":\"2026-09-29T11:34:22+00:00\",\"dateModified\":\"2026-09-29T11:40:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/\"},\"wordCount\":569,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_CellGene.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/\",\"name\":\"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_CellGene.jpg\",\"datePublished\":\"2026-09-29T11:34:22+00:00\",\"dateModified\":\"2026-09-29T11:40:53+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_CellGene.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_CellGene.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/29\\\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-09-29T11:34:22+00:00","article_modified_time":"2026-09-29T11:40:53+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026","datePublished":"2026-09-29T11:34:22+00:00","dateModified":"2026-09-29T11:40:53+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/"},"wordCount":569,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_CellGene.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/","url":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/","name":"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_CellGene.jpg","datePublished":"2026-09-29T11:34:22+00:00","dateModified":"2026-09-29T11:40:53+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_CellGene.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_CellGene.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/29\/nanoscope-therapeutics-to-present-at-meeting-on-the-mesa-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at Meeting on the Mesa 2026"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10328"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10328\/revisions"}],"predecessor-version":[{"id":10333,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10328\/revisions\/10333"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10329"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}